Biofrontera, Inc. (BFRI)

Biofrontera's stock has been impacted by several events in the past six months. The Q3 2025 earnings report revealed an EPS of -$0.62 and revenues of $7.0 million. Biofrontera sold its U.S. license for Xepi® to Pelthos Therapeutics Inc. for up to $10 million. The company completed the purchase of all U.S. rights and assets for Ameluz® and RhodoLED® from Biofrontera AG. Biofrontera submitted an sNDA to the FDA for Ameluz®-PDT for the treatment of superficial basal cell carcinoma (sBCC). The final patient visit in a Phase 1 pharmacokinetic study of Ameluz® for actinic keratoses on the trunk and extremities was completed. Database locks for its Phase 3 actinic keratosis study and Phase 2 acne vulgaris study of Ameluz® PDT occurred, with topline data expected in February 2026. Biofrontera Inc. announced preliminary unaudited Q4 2025 revenues between $17.0 million and $17.5 million. Biofrontera received Nasdaq notices regarding non-compliance with minimum stockholders' equity and minimum bid price requirements, but subsequently regained compliance. The company's stock price experienced a decline of 28.61% between February 7, 2025, and February 6, 2026.

There is an indication of demand seasonality for Biofrontera's products, with weather-related delays in Ameluz sales in Q3 2024. Management expects to see seasonality reflected in the income statement.

Biofrontera, Inc. is a U.S.-based biopharmaceutical company specializing in dermatological conditions, particularly photodynamic therapy (PDT) and topical antibiotics. Its key product is Ameluz®, used with BF-RhodoLED® lamps for treating actinic keratoses (AKs). The company previously commercialized Xepi® for impetigo, but sold the U.S. license in November 2025. Biofrontera employs a "razor-and-blade" model with Ameluz and the RhodoLED lamps.

Biofrontera, Inc. is a U.S.-based biopharmaceutical company with a strategic focus on the U.S. market for its commercialization and regulatory activities related to Ameluz® and RhodoLED® products.

Biofrontera Inc. aims to be a leading specialty dermatology company, focusing on innovative photodynamic therapy. The company emphasizes its commitment to being a trusted and professional partner to healthcare providers and patients, providing superior full-service customer support. Biofrontera also highlights its deep clinical expertise in photodynamic therapy. Recent announcements of record preliminary fourth-quarter 2025 revenues could positively contribute to its brand perception. The company's navigation of Nasdaq listing compliance issues demonstrates its ability to address regulatory challenges.

Biofrontera Inc. has 17 institutional owners and shareholders holding a total of 2,301,320 shares. AIGH Capital Management LLC is a top institutional shareholder with 7.86%. The largest individual shareholder is Beteiligungen Aktiengesellschaft Vv, an insider, holding 4.30% of the company's shares. Biofrontera AG retains a significant stake of 3.75%.